Fulcrum Therapeutics, Inc. announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. Prior to joining Fulcrum, Alan served for several years as chief financial officer of ReViral, which was acquired by Pfizer in 2022.

Previously, he was the chief financial officer and treasurer at Peloton Therapeutics Inc., where he secured a $150 million mezzanine financing and prepared the company for an IPO until the company was acquired by Merck & Co. Alan also served as CFO and treasurer of other biopharmaceutical companies, including Bellicum Pharmaceuticals, Targacept, and Duramed Pharmaceuticals. He spent the early part of his career as a senior internal auditor for Pfizer as well as a certified public accountant (CPA) for KPMG International.

Alan received a B.S. in Accounting from Saint Mary?s College of California, and a master's degree from the Thunderbird School of Global Management. He currently serves on the board of directors of Lung Therapeutics, Inc., a private company.